Carl Borrebaeck, Ph.D., is a Professor and Chair of Immunotechnology and Deputy Vice Chancellor of Lund University and Director of the Strategic Center for Translational Cancer Research – CREATE Health. His research interests include cancer proteomics for early detection and prognosis and antibody engineering for the generation of human therapeutic antibodies. He is a member of the Royal Swedish Academy of Engineering Sciences. In 2009, Dr. Borrebaeck received the AKZO Nobel Science Award for his contributions to cancer proteomics and antibody-based therapy.

Atul Butte, MD, Ph.D., is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics and Medicine and Computer Science at Stanford University and the Lucile Packard Children’s Hospital. Dr. Butte received his MD from Brown University, and trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital in Boston. He earned a PhD in Health Sciences and Technology from Harvard Medical School and MIT. Dr. Butte is founder of Personalis which provides clinical interpretation of whole genome sequences and NuMedii which is finding new uses for drugs. His laboratory builds and applies tools that convert more than 400 trillion points of molecular, clinical, and epidemiological data — measured by researchers and clinicians over the past decade — into diagnostics, therapeutics, and new insights into disease. Dr. Butte has authored more than 120 publications and delivered more than 140 invited presentations in personalized and systems medicine, biomedical informatics, and molecular diabetes—including 30 at the National Academies of Science, Institute of Medicine, National Institutes of Health and NIH-related meetings. Dr. Butte’s research has been featured in the New York Times Science Times and the International Herald Tribune, Wall Street Journal, and San Jose Mercury News.

Andrew Copestake, Ph.D., is the CEO of Swedish Biomimetics 3000 and Managing Director of Swedish Biomimetics 3000 Ltd in the United Kingdom. Before joining Swedish Biomimetics 3000®, he worked for ICON PLC where outsourced product development services for the pharmaceutical, biotechnology and medical device industries are performed. At ICON, Dr. Copestake held a number of senior leadership positions including Vice President and General Manager of the European Early Phase division and Senior Vice President of Global Business Development. Dr. Copestake holds a PhD in Sports and Exercise Physiology from Loughborough University.

Matthew Gardner is the Executive Producer of the weekly NPR program Tech Nation, Chief Business Officer of the Bay Area Council and the former President and CEO of BayBio where he led an organizational transformation resulting in expanded industry engagement in the community.
and with government. He is a frequent advisor to other regions, states and nations on the best practices of building innovation clusters. Matt has served as founder and chair of the life science advisory boards to members of the United States Congress. He has also served on advisory boards for the University of California at Davis and the University of Maryland College Park, the Alameda County Workforce Investment Board, the State of California’s Biotechnology Advisory Board of the California Commission for Economic Development and on the board of the California Association for Local Economic Development. He is chairman of the board of Seeding Labs, a non-profit based in Cambridge, Massachusetts which improves science capacity at institutions in the developing world.

Hank Greely, Ph.D., is the Deane F. and Kate Edelman Johnson Professor of Law and Professor of Genetics at Stanford University. He specializes in ethical, legal, and social issues arising from advances in the biosciences. He chairs the California Advisory Committee on Human Stem Cell Research and the steering committee of the Stanford University Center for Biomedical Ethics, and directs the Stanford Center for Law and the Biosciences. From 2007 to 2010 he was a co-director of the Law and Neuroscience Project. Dr. Greely is a fellow of the American Association for Advancement of Science.

Kenneth Hitchner is Vice President of BioMarin Pharmaceutical Inc.’s Development Sciences Project Management. Prior to BioMarin, Ken worked at Monogram Biosciences where he was a member of the management team and served in numerous leadership positions including Vice President of Pharmaceutical Collaborations and Strategic Director of Business and Product Development. Prior to Monogram Biosciences, Ken was Director of Project Management at Gilead Sciences, and held a number of positions in Quality Control and Product Development at Genentech. Ken earned a Master’s Degree in Biology from San Francisco State University.

Stefan Johansson is Managing Director and CEO of Invest in Skåne. His background is in international business and he has lived and worked in many countries. Sweden’s Region Skåne is home to Medicon Valley, an innovative life sciences cluster stretching from Lund, Sweden, to Copenhagen, Denmark.

Jonas Korlach, Ph.D. is Chief Scientific Officer at Pacific Biosciences. He co-invented the SMRT technology with Dr. Stephen Turner, Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University where Dr. Korlach received both his Ph.D. and his M.S. degrees in Biochemistry and Molecular and Cell Biology. He is the recipient of multiple grants, an inventor on 28 issued U.S. patents, and an author of numerous scientific studies on the principles and applications of SMRT technology. His research has been published in Nature, Science, and PNAS.

Michael Lappen is the Economic Development Coordinator for the City of South San Francisco (SSF). He works closely with State agencies, industry trade groups and developers to attract high technology companies. He has managed projects in advanced planning, zoning, redevelopment, municipal finance, transportation planning, and historic preservation. Michael has also supervised several complex planning projects including the SSF General Plan update, SSF Transit Village Plan and Ordinance, SSF Transportation Improvement Program, the El Camino Real/Chestnut Land Use Plan, and the Genentech Corporate Campus Master Plan.

Jorge Leon, Ph.D. is internationally recognized for his pioneering work in molecular diagnostics. Dr. Leon holds a Ph.D. in cellular and molecular biology from New York University, and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and
Columbia University in NYC. His academic research focused on developing monoclonal antibody-based tumor marker assays and radio-immuno imaging devices which are currently in wide use. In the early 1990s, Dr. Leon transitioned into industry, playing an integral role in establishing and leading the molecular diagnostics laboratories at Quest Diagnostics where he served as Director of Molecular Diagnostics, Senior Director of Biotechnology Development, and Vice President of Applied Genomics. In 2003, Dr. Leon founded Leomics Associates, Inc. a consulting firm committed to helping develop molecular diagnostics and personalized medicine (pharmacogenomics) in the United States and globally. Dr. Leon and his experienced team specializes in identifying breakthrough opportunities and industry trends, and helps start-up businesses, academic centers and established companies successfully build and commercialize innovative business strategies, product pipelines, and test menus.

**Kathryn Lowell** is the Executive Director of Government Affairs at BioMarin where she oversees the development of legislative policy which impacts BioMarin. Previously, she was appointed by Governor Schwarzenegger to develop and execute policy and strategic initiatives to grow a California-based health and life science market. Kathryn was the point person for the Life Sciences industry and led a Personalize Medicine Initiative for the State of California. She was a Board Member of the California Privacy and Security Advisory Board and the California Telehealth Network Advisory Council. She served as the Assistant Secretary for Health at the California Health and Human Services Agency where she helped to create and staff the Biotechnology Council for the State of California. Kathryn graduated from Stanford University and received her Master’s Degree in Public Policy from the University of Southern California.

**Kevin Mullin** is a California State Assemblymember (D- South San Francisco) and Chair of the Select Committee on Biotechnology. Kevin has served as Mayor of South San Francisco and created KM2 Communications – a multimedia production business in South San Francisco which produces public affairs programming. He has been a powerful advocate for life science innovation in South San Francisco and San Mateo County.

**Frank S. Ong, MD,** is the Associate Director of Medical Affairs at Illumina, a leading genomics healthcare/devices company based in San Diego, where he supports Medical Education, Medical Research, Medical Review, and Medical Publication strategies for clinical/research applications of next-generation sequencing and array-based genotyping technologies. He was previously a faculty member of Biomedical Sciences at Cedars-Sinai Medical Center in Los Angeles where he was funded by the National Institutes of Health and by the academic institution for genetics of blood pressure regulation research. Dr. Ong earned his M.D. from the Keck School of Medicine at the University of Southern California. He trained in Family Medicine and Clinical Molecular Genetics at UCLA.

**Christos J. Petropoulos, Ph.D.,** is Vice President of Research and Development and Chief Scientific Officer of Monogram Biosciences and Vice President at Laboratory Corporation of America. In 2010, Dr. Petropoulos assumed responsibility for the Monogram Oncology R&D program and in 2011 was assigned responsibility for the Clinical Research and Medical Education programs. Before coming to Monogram Biosciences, Dr. Petropoulos was a scientist at Genentech where he headed the Research Virology and Molecular Detection Laboratories. Dr. Petropoulos received his Ph.D. in molecular and cell biology from Brown University and trained as a post-doctoral fellow at the NCI Frederick Cancer Research and Development Center. He has co-authored more than 150 scientific journal publications, is co-inventor on 12 issued US patents, and was awarded 12 small business innovative research grants from the National Institutes of Health.
Kimberly J. Popovits, is Chairman of the Board, Chief Executive Officer and President of Genomic Health, Inc. During Kim’s tenure at Genomic Health, the company has launched four genomic diagnostic tests for Breast, Colon and Prostate Cancer, and Ductal Carcinoma In-Situ. Prior to joining Genomic Health, Kim served as Senior Vice President of Marketing and Sales at Genentech where she led the successful commercialization of 14 new therapies. Kim holds a BA in Business from Michigan State University.

Paul Sheives, JD, is the Director of Diagnostics and Personalized Medicine Policy at the Biotechnology Industry Organization (BIO), a trade association that represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 nations. Mr. Sheives heads BIO’s Personalized Medicine and Diagnostics (PMDx) Working Group which is focused on improving legislative, regulatory, intellectual property and reimbursement frameworks to better align incentives for research, development and commercialization of personalized medicine products with patient access to innovative testing and treatment for optimal health outcomes. Prior to joining BIO, Mr. Sheives practiced in two international law firms as a legal associate in the areas of FDA and reimbursement law, and prior to that as a regulatory science advisor. He holds a J.D. from the Georgetown University Law Center and a M.S. in Molecular and Cellular Biology from the University of Texas Southwestern Medical Center at Dallas.

Michael Shuster, JD, Ph.D., is a partner in Fenwick & West’s Intellectual Property Practice, co-chair of the firm’s Life Sciences Group and co-instructor of “A Life Scientist’s Guide to Intellectual Property” at UCSF. He has legal and technical experience representing companies in biotechnology and high technology areas including protein and nucleic acid chemistry, clean technology, high resolution protein structures, proteomics, genomics, combinatorial peptide libraries, vaccine development for viral and autoimmune disorders, transdermal drug delivery systems, liposomal drug formulations and microfluidics devices. Dr. Shuster received his J.D. from the University of San Francisco and a Ph.D. from Columbia University’s Department of Physiology and Molecular Biophysics. While at Columbia he worked with Professor Eric Kandel as part of a team focused on the discovery of mechanisms by which short term memories are stored—work for which Professor Kandel was awarded the Nobel Prize in Medicine in 2000. Dr. Shuster was named one of the Top 25 Biotech Lawyers in California in 2011 and one of the Top 25 Intellectual Property Portfolio Managers in 2009 and 2012 by the Daily Journal. He was also recognized as a “Life Sciences Star” for his outstanding patent work in Euromoney’s LMG Life Sciences 2012.

Mark Sliwkowski, Ph.D. is a Distinguished Staff Scientist in Research Oncology at Genentech, Inc. where he has worked on a number of programs involving drugs directed against the human epidermal growth factor receptor family (also known as the HER or ErbB family). He was involved in the research and development efforts for Herceptin® (trastuzumab) and Tarceva® (erlotinib). Two drugs—Perjeta® (pertuzumab) and Kadcyla® (ado-trastuzumab emtansine)—which resulted from his laboratory’s research have received regulatory approval. In addition, a novel “two-in-one” antibody (MEHD7945A) that targets HER3 and EGFR is about to commence phase II clinical testing in head and neck and colorectal cancer. Dr. Sliwkowski received his Ph.D. in biochemistry from North Carolina State University. He was a postdoctoral fellow in Dr. Theresa Stadtman’s biochemistry laboratory at the NIH National Heart, Lung, and Blood Institute, and later joined Triton Biosciences, Inc., where he studied growth factor receptors and their ligands. Dr. Sliwkowski is an inventor on over 30 issued patents and has authored more than 95 scientific publications.